In attendance:
Andrew Buckler, MS (QIBA Program Director) (Moderator)
P. David Mozley, MD (CT Co-chair)
Maria Athelogou, PhD
Hubert Beaumont
David A. Clunie, MBBS
Charles Fenimore, PhD
Paul Garrett, MD
David Gustafson, PhD
Philip Judy, PhD
Michael McNitt-Gray, PhD
James Mulshine, MD
Kevin O’Donnell
Nicholas Petrick, PhD
Yuanxin Rong, MD, MPH
Ying Tang, PhD
RSNA
Fiona Miller
Madeleine McCoy

Discussion Items:

1. Review of Active Projects
   a. Field Test of Advanced Lung Disease Protocol
      o Protocol version 1.4.1 on web needs correction
      o Reconstruction interval to be corrected (3)
      o Dr. Mozley to complete corrections and send to Mr. Bucker or Joe Koudelik for posting to the Wiki
      o Feedback needed from end users to address the following:
         ▪ How well structure of document worked
         ▪ Suggested changes
         ▪ Specifics that were used and which were ignored
         ▪ Dr. Mozley to request access to copy of actual document or executive summary of used by 6 core labs
   b. Small Pulmonary Mass Profile under development
   c. Groundwork on active projects
      o 1B Group analysis for all lesions complete
      ▪ Call to be scheduled to review inter reader variances
      o 1C on track with imaging acquisition completed
      ▪ Final design of reading study underway
      o 3A establishing study design
      ▪ Characterization of algorithm performance is the goal

2. Lung Cancer Screening
   o Lung cancer screening trial findings may have relevance to QIBA
   o Growth rate of suspicious masses identified by screening could be interpreted as biomarker for lung cancer
   o Consider whether QIBA could be good model for this process
      ▪ Potential for secondary analysis of data from NLST and/or I-ELCAP
      ▪ Possibility of using batch analysis tool being developed with NIST grant
      ▪ Ability of longitudinal study to be concordant with profile/qualification
   o Need to determine appropriateness of lung cancer screening as a QIBA activity
      ▪ Work scope and timeline
      ▪ Parties involved/responsibility
      ▪ How will professional societies be engaged?
      ▪ Is screening protocol sound?
   o Need to determine what QIBA’s involvement should be
      ▪ Funding models
      ▪ Feedback needs to be sought from Technical and Steering committees before decision is made
3. Pharma Data Request Letter (deferred to next call)
4. RSNA Abstracts (deferred to next call): Abstract Deadline, March 31, 2011

Next Steps:

- Mr Buckler to post corrected protocol version 1.4.1 to the WIKI
- VOL-CT April 21st meeting in Chicago to be confirmed
- Additional discussion on lung cancer screening, pharma data request letter, and RSNA abstracts to be included in subsequent general business calls.